Data presented at American Diabetes Association (ADA) 2020
Please refer to the ADA website directly for oral presentations and posters available for registered attendees at: https://professional.diabetes.org/scientific-sessions or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).
Ferrannini E, Baldi S, Scozzaro T, et al. The redox balance predicts both cardiovascular (CV) and renal outcomes in CANVAS.
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/139-LB
Li J, Sen T, Neal B, et al. Association between the inflammatory marker GDF-15 and kidney disease progression: results from the CANVAS Trial.
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1120-P
Li J, Neal B, Heerspink HL, et al. Mediators of the effects of canagliflozin (CANA) on heart failure (HF) and CV death in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1130-P
Li J, Jardine MJ, Neal B, et al. Effect of canagliflozin on total hospitalization for heart failure events in patients with type 2 diabetes and chronic kidney disease.
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/27-OR
Oshima M, Jardine MJ, Agarwal R, et al. Acute declines in EGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE.
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/26-OR
Peters K, Xu J, Bringans S, et al. Validation of the PromarkerD Test for predicting renal decline in type 2 diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS).
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1118-P
Pilon D, Durkin M, Manceur A, Ghelerter I, Lafeuille M, Lefebvre P. Comparison of hospitalization for heart failure (HHF) among patients with type 2 diabetes mellitus (T2DM) and macroalbuminuria initiated on canagliflozin (CANA) or a DPP-4.
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1142-P
Sattar N, Xu J, Butler J, et al. Stress cardiac biomarkers and adverse cardiac outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS).
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1123-P
Sen T, Li J, Neal B, et al. Biomarkers of tubular injury and effects of canagliflozin in the CANVAS Trial.
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1098-P